Peroxisome proliferator-activated receptor-γ agonist-mediated inhibition of cell growth is independent of apoptosis in human epidermoid carcinoma A431 cells

Li,Qian; Peng,Yu‑Sheng; Chen,Ping‑Jiao; Wang,Meng‑Lei; Cao,Can; Xiong,Hao; Zhang,Jing; Chen,Ming‑Hua; Peng,Xue‑Biao; Zeng,Kang

doi:10.3892/ol.2018.8136

Peroxisome proliferator-activated receptor-γ agonist-mediated inhibition of cell growth is independent of apoptosis in human epidermoid carcinoma A431 cells

Authors:
- Qian Li
- Yu‑Sheng Peng
- Ping‑Jiao Chen
- Meng‑Lei Wang
- Can Cao
- Hao Xiong
- Jing Zhang
- Ming‑Hua Chen
- Xue‑Biao Peng
- Kang Zeng
View Affiliations

Affiliations: Department of Dermatology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
Published online on: February 28, 2018 https://doi.org/10.3892/ol.2018.8136
Pages: 6578-6584

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Evidence suggests that peroxisome proliferator activated receptor‑γ (PPAR‑γ) acts as a tumor suppressor in multiple types of cancer; however, the role of action of PPAR‑γ on human epidermoid carcinoma is unclear. The present study investigated the effects of a PPAR‑γ agonist, rosiglitazone, on human epidermoid carcinoma cell growth using the A431 cell line. The effects of rosiglitazone on cell viability and proliferation were evaluated with MTS and [3H] thymidine incorporation assays. The effects of rosiglitazone on the cell cycle and apoptosis were analyzed by flow cytometry, and western blotting. It was identified that rosiglitazone inhibited A431 cell proliferation in a dose‑dependent manner, increased the proportion of cells in the G1 phase, but did not affect apoptosis. Consistently, there was a significant decrease in the expression of cell proliferation‑associated proteins, including cyclin D1, cyclin‑dependent kinase (Cdk)2 and Cdk4 in A431 cells treated with rosiglitazone. This decrease was rescued by a selective antagonist of PPAR‑γ or specific PPAR‑γ small interfering RNAs. However, the ratio of B‑cell lymphoma 2 (Bcl‑2) to Bcl‑2 associated X protein, which is associated with cell apoptosis, was not affected by these treatments. The data of the present study suggest that the PPAR‑γ agonist rosiglitazone inhibits human epidermoid carcinoma cell growth through regulating the expression of the cell cycle‑associated proteins, and that this effect is independent of apoptosis.

View Figures

View References

1	Sauter ER, Herlyn M, Liu SC, Litwin S and Ridge JA: Prolonged response to antisense cyclin D1 in a human squamous cancer xenograft model. Clin Cancer Res. 6:654–660. 2000.PubMed/NCBI
2	Trakatelli M, Ulrich C, del Marmol V, Euvrard S, Stockfleth E and Abeni D: Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: Accurate and comparable data are needed for effective public health monitoring and interventions. Br J Dermatol. 156 Suppl 3:S1–S7. 2007. View Article : Google Scholar
3	Karia PS, Han J and Schmults CD: Cutaneous squamous cell carcinoma: Estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol. 68:957–966. 2013. View Article : Google Scholar : PubMed/NCBI
4	Dong JT: Anticancer activities of PPARγ in breast cancer are context-dependent. Am J Pathol. 182:1972–1975. 2013. View Article : Google Scholar : PubMed/NCBI
5	Issemann I and Green S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 347:645–650. 1990. View Article : Google Scholar : PubMed/NCBI
6	Kersten S, Desvergne B and Wahli W: Roles of PPARs in health and disease. Nature. 405:421–424. 2000. View Article : Google Scholar : PubMed/NCBI
7	Elstner E, Müller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D and Koeffler HP: Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA. 95:8806–8811. 1998. View Article : Google Scholar : PubMed/NCBI
8	Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C and Spiegelman BM: Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med. 4:1046–1052. 1998. View Article : Google Scholar : PubMed/NCBI
9	Motomura W, Okumura T, Takahashi N, Obara T and Kohgo Y: Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells. Cancer Res. 60:5558–5564. 2000.PubMed/NCBI
10	Inoue K, Kawahito Y, Tsubouchi Y, Kohno M, Yoshimura R, Yoshikawa T and Sano H: Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists. Biochem Biophys Res Commun. 287:727–732. 2001. View Article : Google Scholar : PubMed/NCBI
11	Nicol CJ, Yoon M, Ward JM, Yamashita M, Fukamachi K, Peters JM and Gonzalez FJ: PPARgamma influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis. Carcinogenesis. 25:1747–1755. 2004. View Article : Google Scholar : PubMed/NCBI
12	Mao-Qiang M, Fowler AJ, Schmuth M, Lau P, Chang S, Brown BE, Moser AH, Michalik L, Desvergne B, Wahli W, et al: Peroxisome-proliferator-activated receptor (PPAR)-gamma activation stimulates keratinocyte differentiation. J Invest Dermatol. 123:305–312. 2004. View Article : Google Scholar : PubMed/NCBI
13	Kundoor V, Zhang X, Bommareddy A, Khalifa S, Fahmy H and Dwivedi C: Chemopreventive effects of sarcotriol on ultraviolet B-induced skin tumor development in SKH-1 hairless mice. Mar Drugs. 5:197–207. 2007. View Article : Google Scholar : PubMed/NCBI
14	Sarfaraz S, Adhami VM, Syed DN, Afaq F and Mukhtar H: Cannabinoids for cancer treatment: Progress and promise. Cancer Res. 68:339–342. 2008. View Article : Google Scholar : PubMed/NCBI
15	He G, Thuillier P and Fischer SM: Troglitazone inhibits cyclin D1 expression and cell cycling independently of PPARgamma in normal mouse skin keratinocytes. J Invest Dermatol. 123:1110–1119. 2004. View Article : Google Scholar : PubMed/NCBI
16	Chen Z, He P, Ding X, Huang Y, Gu H and Ni X: PPARγ stimulates expression of L-type amino acid and taurine transporters in human placentas: The evidence of PPARγ regulating fetal growth. Sci Rep. 5:126502015. View Article : Google Scholar : PubMed/NCBI
17	Wu M, Melichian DS, Chang E, Warner-Blankenship M, Ghosh AK and Varga J: Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. Am J Pathol. 174:519–533. 2009. View Article : Google Scholar : PubMed/NCBI
18	Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S and Spiegelman BM: Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell. 1:465–470. 1998. View Article : Google Scholar : PubMed/NCBI
19	Jiang WG, Redfern A, Bryce RP and Mansel RE: Peroxisome proliferator activated receptor-gamma (PPAR-gamma) mediates the action of gamma linolenic acid in breast cancer cells. Prostaglandins Leukot Essent Fatty Acids. 62:119–127. 2000. View Article : Google Scholar : PubMed/NCBI
20	Youssef J and Badr M: Peroxisome proliferator-activated receptors and cancer: Challenges and opportunities. Br J Pharmacol. 164:68–82. 2011. View Article : Google Scholar : PubMed/NCBI
21	Kitamura S, Miyazaki Y, Shinomura Y, Kondo S, Kanayama S and Matsuzawa Y: Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res. 90:75–80. 1999. View Article : Google Scholar : PubMed/NCBI
22	Tsujie M, Nakamori S, Okami J, Hayashi N, Hiraoka N, Nagano H, Dono K, Umeshita K, Sakon M and Monden M: Thiazolidinediones inhibit growth of gastrointestinal, biliary, and pancreatic adenocarcinoma cells through activation of the peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha pathway. Exp Cell Res. 289:143–151. 2003. View Article : Google Scholar : PubMed/NCBI
23	Itami A, Watanabe G, Shimada Y, Hashimoto Y, Kawamura J, Kato M, Hosotani R and Imamura M: Ligands for peroxisome proliferator-activated receptor gamma inhibit growth of pancreatic cancers both in vitro and in vivo. Int J Cancer. 94:370–376. 2001. View Article : Google Scholar : PubMed/NCBI
24	Kawa S, Nikaido T, Unno H, Usuda N, Nakayama K and Kiyosawa K: Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR gamma ligand troglitazone. Pancreas. 24:1–7. 2002. View Article : Google Scholar : PubMed/NCBI
25	Altiok S, Xu M and Spiegelman BM: PPARgamma induces cell cycle withdrawal: Inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev. 11:1987–1998. 1997. View Article : Google Scholar : PubMed/NCBI
26	Ramachandran L, Manu KA, Shanmugam MK, Li F, Siveen KS, Vali S, Kapoor S, Abbasi T, Surana R, Smoot DT, et al: Isorhamnetin inhibits proliferation and invasion and induces apoptosis through the modulation of peroxisome proliferator-activated receptor γ activation pathway in gastric cancer. J Biol Chem. 287:38028–38040. 2012. View Article : Google Scholar : PubMed/NCBI
27	Lee NJ, Oh JH, Ban JO, Shim JH, Lee HP, Jung JK, Ahn BW, Yoon DY, Han SB, Ham YW and Hong JT: 4-O-methylhonokiol, a PPARγ agonist, inhibits prostate tumour growth: p21-mediated suppression of NF-κB activity. Br J Pharmacol. 168:1133–1145. 2013. View Article : Google Scholar : PubMed/NCBI
28	Wang S, Awad KS, Elinoff JM, Dougherty EJ, Ferreyra GA, Wang JY, Cai R, Sun J, Ptasinska A and Danner RL: G protein-coupled receptor 40 (GPR40) and peroxisome proliferator-activated receptor γ (PPARγ): AN integrated two-receptor signaling pathway. J Biol Chem. 290:19544–19557. 2015. View Article : Google Scholar : PubMed/NCBI